Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

Chen Wang,1,2 Kathy L. McGraw,2 Amy F. McLemore,2 Rami Komrokji,2 Ashley A. Basiorka,2 Najla Al Ali,2 Jeffrey E. Lancet,2 Eric Padron,2 Olivier Kosmider,3 Michaela Fontenay,4 Pierre Fenaux,4 Alan F. List1# and David A. Sallman2#

1Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL, USA; 2Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 3Service d’Hématologie Biologique, Assistance Publique-Hôpitaux de Paris. Centre-Université de Paris, Hôpital Cochin, Paris, France and 4Groupe Francophone des Myélodysplasies, Hôpital Saint Louis, Paris, France

#AFL and DAS contributed equally as co-senior authors.

Correspondence:
DAVID A. SALLMAN - david.sallman@moffitt.org
doi 10.3324/haematol.2021.278855
### Supplement table. Patient’s characteristics based on treatment

| Median (range) or N (%) | All (n = 69) | Lenalidomide (n = 31) | Lenalidomide plus epoetin β (n = 38) | P* |
|------------------------|-------------|-----------------------|-------------------------------------|----|
| Demographics           |             |                       |                                     |    |
| Age (years)            | 73 (46-86)  | 73 (54-79)            | 74 (46-86)                          | 0.089 |
| Male (%)               | 48 (69.6)   | 19 (61.3)             | 29 (76.3)                           | 0.177 |
| Clinical features      |             |                       |                                     |    |
| Hemoglobin (g/dL)      | 8.1 (6.3-10.0) | 7.8 (6.8-9.6) | 8.1 (6.3-10.0) | 0.064 |
| ANC (/mm³)             | 2.1 (0.15-10.06) (n = 67) | 2.00 (0.15-10.06) (n = 30) | 2.60 (0.40-5.70) (n = 37) | 0.695 |
| Platelet (10³/mm³)     | 235 (58-587) (n = 67) | 209 (68-494) (n = 30) | 242 (58-587) (n = 37) | 0.854 |
| Serum EPO > 200 mU/mL (%) | 27 (48.2) (n = 56) | 12 (n = 29) | 15 (n = 27) | 0.289 |
| Bone marrow blast > 2% (%) | 27 (39.1) | 8 (25.8) | 19 (50.0) | 0.041 |
| Bone marrow erythroblast (%) | 28.9 (1.0-79.0) (n = 67) | 36.7 (1.0-65.0) (n = 30) | 27.0 (4.4-79.0) (n = 37) | 0.308 |
| RARS (%)               | 38 (55.1)   | 17 (54.8)             | 21 (55.3)                           | 0.972 |
| Favorable karyotype (%)| 59 (86.8)   | 27 (87.1)             | 32 (86.5)                           | 1.000 |
| Splicesome mutation    |             |                       |                                     |    |
| SF3B1 (%)              | 52 (75.4)   | 26 (83.9)             | 26 (68.4)                           | 0.168 |
| U2AF (%)               | 0 (0.0)     | 0 (0.0)               | 0 (0.0)                             | 1.000 |
| SRSF2 (%)              | 6 (8.7)     | 4 (12.9)              | 2 (5.3)                             | 0.397 |
| ZRSR2 (%)              | 5 (7.2)     | 2 (6.5)               | 3 (7.9)                             | 1.000 |
| Epigenetic mutation    |             |                       |                                     |    |
| TET2 (%)               | 34 (49.3)   | 14 (45.2)             | 20 (52.6)                           | 0.537 |
| IDH (%)                | 2 (2.9)     | 2 (6.5)               | 0 (0.0)                             | 0.198 |
| DNMT3A (%)             | 13 (18.9)   | 6 (19.4)              | 7 (18.4)                            | 0.921 |
| ASXL1 (%)              | 12 (17.4)   | 8 (25.8)              | 4 (10.5)                            | 0.119 |
| EZH2 (%)               | 2 (2.9)     | 0 (0.0)               | 2 (5.3)                             | 0.498 |
| Number of mutations    | 2 (0-6)     | 2 (1-6)               | 2 (0-6)                             | 0.515 |
| IPSS low risk (%)      | 33 (48.5) (n = 68) | 16 (51.6) | 17 (45.9) (n = 37) | 0.641 |
| Biomarker              |             |                       |                                     |    |
| ASC specks > median (%)| 34 (49.3)   | 11 (35.5)             | 23 (60.5)                           | 0.039 |
| Treatment              |             |                       |                                     |    |
| Prior responder to recombinant EPO (%) | 24 (35.8) (n = 67) | 9 (29.0) (n = 31) | 15 (41.7) (n = 36) | 0.282 |
| Responder (%)          | 28 (40.6)   | 7 (22.6)              | 21 (55.3)                           | 0.006 |

* Continuous variables were compared by Mann-Whitney test, and categorical variables were compared using Fisher’s exact test or chi-square test, as appropriate.

Abbreviations: ANC, absolute neutrophil count; EPO, erythropoietin; RARS, refractory anemia with ring sideroblasts; IPSS, international prognostic score system; ASC, apoptosis-associated speck-like protein containing a CARD.